Home›Articles›CUPID2 and the limits of a sound rationale for heart failure gene therapyArticleCUPID2 and the limits of a sound rationale for heart failure gene therapyArticlesConnectionsSourcesComments (0)Reader Challenges (0)ConnectionsArticle OnMydicar, Drugs and Medicinal Substances Well-attested SourcesCelladon's Mydicar Fails Phase IIb Trial (GEN)Body, primary endpoint resultQuote, Body, primary endpoint resultMydicar showed only a statistically-insignificant 6% improvement compared to a placebo in reduction of the risk of heart-failure related hospitalization.View the SourceMedicine Atlas Original Articlestier 1Comments (0)No comments yet. Be the first to share a thought.Sign in to join the discussion.Reader Challenges (0)No disputes yet. Spotted an error or a better source? Open the first one.Sign in to dispute this or suggest a correction.